MyoMobile Study: App-based Activity Coaching in Patients with Heart Failure and Preserved Ejection Fraction

NCT ID: NCT04940312

Last Updated: 2024-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

193 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-11

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MyoMobile study is a single-center, randomized, controlled three-armed cohort study with prospective data collection to investigate the effect of a personalized mobile health intervention compared to usual care on the physical activity levels in patients with heart failure and preserved ejection fraction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure (HF) affects more than 15 million people in Europe and represents the leading cause of hospitalization. The prevalence of HF is increasing, which has been attributed to an ageing population with subsequently higher prevalence of predisposing risk factors (e.g. arterial hypertension, type-2-diabetes, obesity), a better survival, and more effective treatment of precursors (e.g. myocardial infarction). In the community, heart failure with preserved ejection fraction (HFpEF) is the most common HF phenotype. Currently, the benefit of medical therapies is limited to patients with heart failure with reduced ejection fraction (HFrEF) only, whereas no specific medical therapy is currently approved for patients with HFpEF.

In HF patients, physical inactivity and a sedentary lifestyle lead to disease progression and increased mortality, and an increase of physical activity is positively correlated with improved outcome. Guidelines from the Heart Failure Society of America recommend at least 30 minutes of moderate-intensity activity for ≥ 5 days/week (i.e. at least 150 min/week). Unfortunately, exercise recommendations are poorly implemented in daily clinical practice and even patients enrolled in supervised exercise training programs have been reported to show low adherence.

The MyoMobile study has been designed to assess the effect of a 12-week, app-based coaching program on physical activity in patients with HFpEF. Physical activity including daily step count will be assessed by accelerometry and, in addition, a pedometer will be used to measure the daily step count and provide direct feedback to the patient. Accelerometers provide an objective and continuous assessment of physical activity during patients' daily life over longer periods and may therefore reflect the true effect of the activity coaching intervention on physical activity more accurately than intermittent supervised exercise tests such as the six minute walk test. These efforts are complemented by a comprehensive (sub)clinical and molecular characterization of HFpEF patients at baseline and after the follow-up period of 12 weeks. In order to evaluate the potential effect of awareness for physical activity and of surveillance, due to participants wearing a pedometer throughout the study period, two intervention groups will be investigated. This will allow for the effect of an individualized, app-based coaching intervention, compared to standard care in patients with HFpEF, to be deciphered.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Heart Failure, Diastolic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care Group

Individuals with heart failure receiving standard medical care

No Intervention: Observational Cohort

Intervention Type BEHAVIORAL

no Intervention

Intervention Group 1 (pedometer-monitoring only)

Individuals with heart failure receiving a pedometer for measurement of daily step count

Intervention Group 1

Intervention Type BEHAVIORAL

pedometer-based tracking of physical activity

Intervention Group 2 (app-based coaching)

Individuals with heart failure receiving an individualized, app-based physical activity coaching on the basis of pedometer-based assessment of daily step count

App-based physical activity coaching

Intervention Type BEHAVIORAL

Individualized app-based coaching via a smartphone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

App-based physical activity coaching

Individualized app-based coaching via a smartphone

Intervention Type BEHAVIORAL

No Intervention: Observational Cohort

no Intervention

Intervention Type BEHAVIORAL

Intervention Group 1

pedometer-based tracking of physical activity

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 45 years
* Diagnosis of HFpEF

* LVEF \> 40% by any imaging modality at screening within 4 months prior to study entry
* Current HF symptoms as defined as presence of dyspnea according to New York Heart Association \[NYHA\] functional class I to III at screening visit
* Stable HF treatment for at least 4 weeks prior to screening
* At least one of the following 3 criteria need to be fulfilled: (1) NT-proBNP ≥ 300pg/ml; (2) Hospitalization for HF within the past 12 months; (3) Symptom(s) of HF requiring treatment with diuretic(s) for at least 30 days prior to screening visit
* Wearing time of the physical activity monitor for at least 4 days during the baseline assessment
* Average daily step count during baseline assessment ≥ 1,000 steps per day and \< 10,000 steps per day

Exclusion Criteria

* Acute decompensated HF requiring augmented therapy with diuretic agents, vasodilator agents, and/or inotropic drugs
* Participants who are non-ambulatory managed or use mobility assistive devices such as motorized devices or wheelchairs
* Acute coronary syndrome (including myocardial infarction), cardiac surgery, other major cardiovascular surgery or urgent percutaneous coronary intervention (PCI) within 3 months prior to visit 1 or an elective PCI within 30 days after study enrolment
* Probable alternative diagnoses that in the opinion of the investigator account for the patient's HF symptoms (i.e., dyspnea, fatigue)
* Participants with physical activity impairment primarily due to conditions other than HF such as:

* Participants unwilling or unable to wear or to operate study measurement devices for the phases required
* Exertional angina
* Inflammatory or degenerative joint disease
* Peripheral vascular disease
* Neurologic disease affecting activity or mobility (e.g. peripheral neuropathy)
* Foot ulcer (e.g. diabetic foot syndrome)
* Prosthetic limbs
* Current chemotherapy and/or radiation therapy for treatment of active cancer
* Medical or psychological conditions that would jeopardize an adequate and orderly conduct or completion of the study
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role collaborator

McRoberts B.V.

UNKNOWN

Sponsor Role collaborator

Umana Medical Technologies Ltd.

UNKNOWN

Sponsor Role collaborator

International Business Machines (IBM)

INDUSTRY

Sponsor Role collaborator

Johannes Gutenberg University Mainz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Philipp Wild, MD, MSc

Univ.-Prof. Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philipp Wild, Univ.-Prof. Dr. med., MSc

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Mainz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center of the Johannes Gutenberg-University Mainz

Mainz, Rhineland-Palatinate, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Zeid S, Prochaska JH, Schuch A, Trobs SO, Schulz A, Munzel T, Pies T, Dinh W, Michal M, Simon P, Wild PS. Personalized app-based coaching for improving physical activity in heart failure with preserved ejection fraction patients compared with standard care: rationale and design of the MyoMobile Study. Eur Heart J Digit Health. 2025 Jan 30;6(2):298-309. doi: 10.1093/ehjdh/ztae096. eCollection 2025 Mar.

Reference Type DERIVED
PMID: 40110212 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMCM-2020EPI06

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The SMARTEX Heart Failure Study
NCT00917046 COMPLETED NA
Heart Failure Activity Coach Study
NCT05235763 COMPLETED NA